EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

By Marjolein Peters, D. Symmons, D. Mccarey, B. Dijkmans, P. Nicola, T. Kvien, I. McInnes, H. Haentzschel, M. González-Gay, S. Provan and 8 more. Annals of the Rheumatic Diseases, 2009

1,407 citations recorded by the source corpus.

Subfields: Nephrology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/01ffe36651373471f3d2c17df9d0708107e71ef7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Rheumatology

1. I. Graham
2. J. Smolen
3. I. McInnes
4. S. Gaffen

Citations in the corpus

• Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA) (2013, background): “Detailed comparisons of the baseline characteristics for each individual country are provided in online supplementary tables S1 and S2.”
• National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. (2015, background): “The European League Against Rheumatism published recommendations in 2009 for cardiovascular risk management in RA and other inflammatory diseases relying heavily on expert opinion.(718) These recommendations have not been adopted into clinical practice in the United States.”
• Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease (2019, background): “Furthermore, psoriasis has even been characterized as an independent risk factor for cardiovascular disease [4] where patients presenting with psoriasis or associated inflammatory arthritis are recommended by the European League Against Rheumatism to undergo cardiovascular therapy [159].”
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “Such evidence has now been implemented in some national risk scores(58) and European guidelines.(177) Evidence in psoriasis is less rigorous, but a recent paper demonstrates broadly comparable CV risks in RA and in early severe psoriasis.”
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, background): “Such evidence has now been implemented in some national risk scores(58) and European guidelines.(177) Evidence in psoriasis is less rigorous, but a recent paper demonstrates broadly comparable CV risks in RA and in early severe psoriasis.”
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011, background): “Autoimmune diseases, including rheumatoid arthritis, SLE, psoriasis, and antiphospholipid syndrome, are characterized by enhanced atherosclerosis and consequently higher CV morbidity and mortality rates compared with the general population.(186) – 188”
• 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis (2011, background): “Regarding the management of cardiovascular risk there are recent EULAR recommendations that propose an annual risk assessment related to national guidelines.”
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, neutral): “Such evidence has now been implemented in some national risk scores [58] and European guidelines [177].”